The 2nd Oligonucleotides CMC and Analytical Development Summit return this August to Boston. With the unprecedented growth of the oligonucleotides market, reaching $2b by 2027 and with over 250 in the clinical phase of drug development, we now seek to unlock the potential of oligonucleotides beyond rare disease to treat large patient populations for undruggable targets. In the last 12 months alone, there have been a number of advances in the field with Switch Therapeutics advancing their first RNAi technology, Avidity turbocharging their antibody-oligo conjugate and Ansa Biotech successfully synthesizing the world's longest oligonucleotide! Despite this, drug developers still face challenges in manufacturability and lack of concrete regulatory protocols.
Read on oligos-cmc-analytical-development.com
Continue reading at oligos-cmc-analytical-development.com
August 29 to August 31, 2023
Meliá Berlin, 103 Friedrichstraße, Berlin, 10117, Germany
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2023 Netspective Media LLC. All Rights Reserved.
Built on May 30, 2023 at 4:29am